What Is FGF10? Definition and What Research Reports

Definition

FGF10 stands for fibroblast growth factor 10, a secreted signalling protein encoded by the FGF10 gene and classified within the FGF7 subfamily of the fibroblast growth factor family. It is produced largely by mesenchymal cells — the loose connective tissue that sits beneath and around epithelial sheets — and it acts in a paracrine fashion, meaning it diffuses a short distance and binds receptors on nearby cells rather than circulating widely as a hormone. Its principal receptor is the “b” splice variant of fibroblast growth factor receptor 2 (FGFR2b), which is expressed on epithelial cells; this ligand–receptor pairing is the reason FGF10 is so often described as a mesenchymal-to-epithelial signal. In laboratory writing, “FGF10” may refer to the gene, the messenger RNA, the protein itself, or recombinant protein used as a reagent, and the intended meaning is usually clear from context.

What Class of Molecule Is It?

FGF10 is a protein, not a short synthetic peptide. The human protein is a little over 200 amino acids in its unprocessed form, includes a signal sequence directing it out of the cell, and carries a heparin-binding region that tethers it to heparan sulfate in the extracellular matrix. That matrix binding is functionally important: it keeps FGF10 concentrated near its source and shapes the gradients that developing tissues read.

Structural work has examined how FGF10 engages its receptor. Researchers studying receptor recognition reported that N-terminal helix formation and a dimer-to-monomer transition were involved in the specific recognition of FGFR2b by FGF10 (PMID 40794773). A separate biophysical study reported that increasing the thermal stability of FGF10 led to ectopic signalling during development, indicating that the protein's stability, and not only its amino acid sequence, influenced where its signal was received (PMID 40257501).

Where It Comes From

Endogenously, FGF10 is expressed by mesenchymal and stromal cells in many tissues during embryonic development and, at lower levels, in adult tissue. For laboratory use, the protein studied is typically recombinant — produced in bacterial or mammalian expression systems and supplied as a research-use-only reagent. Recombinant FGF10 is not an approved drug product in the United States; related FGF-family biology did yield one approved protein (palifermin, a truncated form of the related ligand FGF7/KGF), but FGF10 itself appears in the literature as an experimental agent and a developmental signal rather than a marketed therapeutic.

How the Term Is Used in Peptide and Protein Research

Across the published literature, “FGF10” tends to appear in four broad contexts:

• Developmental biology. FGF10 is one of the classic mesenchymal cues that instructs epithelial branching and organ patterning. An early developmental study reported that FGF10 signalling controlled stomach morphogenesis (PMID 17196193), and a 2025 report described how balancing SHH against BMP/FGF10 inputs specified tuberal hypothalamic neurons and glia (PMID 40482693).
• Organoid and regeneration models. A 2024 study reported that FGF7 and FGF10 promoted a fate transition of human epidermal cell-derived organoids toward an eccrine gland phenotype (PMID 39247826), a use case in which the protein functions as a defined culture additive rather than a therapy.
• Injury and stress models. Several animal studies have used exogenous FGF10 to probe tissue responses to ischaemia, trauma or infection.
• Cancer and receptor signalling. Because FGFR2 is an oncogenic driver in some tumours, the FGF10/FGFR2 axis is studied as a signalling vulnerability rather than as something to supply.

What the Published Literature Reports

Most of the primary literature on FGF10 is preclinical — cell culture, organoid and rodent work. The table below summarises the direction of findings in the cited papers; it is descriptive of what was reported and is not a statement about human outcomes.

Two consistent themes run through this work. First, the reported effects are receptor-driven: the seizure study attributed its findings to FGFR2/CALB1 signalling (PMID 41121240), which is consistent with structural work showing that FGF10 recognises FGFR2b specifically (PMID 40794773). Second, the injury models repeatedly implicate intracellular stress-handling pathways — autophagy in the renal study (PMID 30532765) and mitophagy in the sepsis lung study (PMID 42153339) — rather than a single simple mechanism.

FGF10 Signalling in Cancer Biology: What Studies Report

Growth factor signalling is not uniformly beneficial, and the oncology literature treats the FGF10/FGFR2 axis as a potential driver rather than a protective factor. Researchers examining cholangiocarcinoma cells reported that FGF10/FGFR2 signalling represented a therapeutically targetable vulnerability in ligand-responsive cells — that is, the goal in that setting was to block the pathway (PMID 37369494). In haematology, a translational study evaluated FGF10 and FGF17 as prognostic and drug-response markers in acute myeloid leukemia (PMID 34731724). Developmental work adds a further note of caution about dysregulated signalling: the study of thermally stabilised FGF10 reported ectopic signalling during development, meaning the signal reached places it normally would not (PMID 40257501). Taken together, these reports describe a molecule whose biological consequences depend heavily on context, cell type and the amount and location of signalling.

Adverse Events in Humans

The verified literature summarised on this page consists of cell-culture, organoid and animal studies together with structural and biomarker analyses; it does not contain human safety or tolerability data for administered FGF10, and none is described here.

Related Terms

• FGFR2b — the epithelial receptor splice variant that FGF10 binds with specificity (PMID 40794773).
• FGF7 (KGF) — the closest family relative, used alongside FGF10 in the eccrine-gland organoid work (PMID 39247826).
• Paracrine signalling — short-range cell-to-cell communication, the mode in which FGF10 acts.
• Branching morphogenesis — the developmental process FGF10 helps pattern, illustrated by the stomach morphogenesis study (PMID 17196193).

Scope and Limitations

Readers comparing FGF10 to short research peptides should note the differences in size and handling: FGF10 is a folded, heparin-binding protein whose activity depends on conformation and stability, as the thermal-stability study illustrated (PMID 40257501). Findings in rodents, cell lines and organoids do not automatically translate to people, and none of the work cited here established a human dosing framework. This page is for educational purposes only and is not medical advice; consult a licensed physician about any health decision or medical condition.

References

• FGF7 and FGF10 Promote Fate Transition of Human Epidermal Cell-derived Organoids to an Eccrine Gland Phenotype (International Journal of Biological Sciences, 2024)
• Balancing SHH and BMP/FGF10 to specify tuberal hypothalamic neurons and glia (Developmental Biology, 2025)
• FGF10 ameliorates epileptic seizures and related cognitive dysfunction via the FGFR2/CALB1 signaling pathway (Journal of Translational Medicine, 2025)
• Increased thermal stability of FGF10 leads to ectopic signaling during development (Cellular and Molecular Life Sciences, 2025)
• CDC5L facilitates cardiomyocyte proliferation and ameliorates myocardial ischemia-reperfusion injury via modulation of the FGF10-YAP axis (Acta Biochimica et Biophysica Sinica, 2025)
• FGF10 mitigated sepsis-induced pulmonary coagulopathy via Nrf2/PINK1/Parkin-modulated mitophagy (American Journal of Respiratory Cell and Molecular Biology, 2026)
• FGF10/FGFR2 Signaling: Therapeutically Targetable Vulnerability in Ligand-responsive Cholangiocarcinoma Cells (In Vivo, 2023)
• FGF10 Protects Against Renal Ischemia/Reperfusion Injury by Regulating Autophagy and Inflammatory Signaling (Frontiers in Genetics, 2018)
• N-terminal helix formation and dimer-monomer transition of FGF10 in specific recognition of FGFR2b (The FEBS Journal, 2025)
• FGF10 signaling controls stomach morphogenesis (Developmental Biology, 2007)
• FGF10/FGF17 as prognostic and drug response markers in acute myeloid leukemia (Current Research in Translational Medicine, 2022)
• FGF10 Attenuates Experimental Traumatic Brain Injury through TLR4/MyD88/NF-κB Pathway (Cells, Tissues, Organs, 2020)